What MCAT Will Do to You

April 2026

Put a chronic methamphetamine user in a PET scanner and the dopamine transporter loss is 24 to 30 percent in the striatum.8 Your brain normally loses about 7 percent of that capacity per decade after your twenties. These users had aged their dopamine system by forty years in a few years of use. You can see it on the scan.

Two independent population studies, one tracking Utah medical records for fifteen years,11 one using California hospital discharge data,12 both found roughly three times the risk of Parkinson's disease in amphetamine users. Cocaine users in the same data had no elevated risk. This is specific to how stimulants damage dopamine neurons.

Then there is memory. A 2025 meta-analysis looked at people who had stopped taking MDMA at least six months earlier. Their verbal memory was not better. It was worse than the people still using.3 And the length of time they had been clean made no difference. One year abstinent or five: the same deficit.

A study of 997 former MDMA users, clean for an average of five years, found them worse than non-users on ten out of thirteen psychological measures: depression, impulsivity, sleep quality, memory.7 On two measures they were worse than people still using.

A Swedish national register tracked 5,018 people with amphetamine-type stimulant diagnoses from 2013 to 2017. Their mortality rate was 12.4 times the general population.24

Nobody has studied mephedrone users for ten years. The drug arrived around 2009, got banned in 2010, and the science never caught up. But mephedrone is not a new invention. It hits serotonin the way MDMA does and dopamine the way methamphetamine does, at the same time.1 MDMA and methamphetamine have over twenty years of brain scans, population data, and cognitive testing between them. What follows is what that research found on each side, what it predicts for the drug that combines them, and what recovers if you stop.

• • •

Dopamine is what lets you feel pleasure from ordinary things. Food. Conversation. Finishing a task. Someone's company. Chronic stimulant use depletes the system that produces it. The 24 to 30 percent transporter loss Volkow's team measured is the equivalent of forty years of normal ageing.8

The receptor loss is what makes ordinary life stop being enough. The receptors that register everyday reward were reduced by 16 percent.9 That reduction correlated with impulsivity. Lower receptors, worse decisions. The part of the brain that weighs consequences became less active in proportion to the dopamine deficit.

One study followed methamphetamine users for nine months.10 Of the six who relapsed, all had low dopamine receptor levels at baseline. Of the ten who stayed clean, their receptor levels were normal. Your dopamine status predicts whether you can stop.

Parkinson's usually arrives after sixty. These users were being diagnosed decades earlier. The mechanism is arithmetic: stimulant use takes a percentage of your dopamine neurons, normal ageing takes the rest, and when the total loss crosses a threshold, the tremor starts. Young methamphetamine users also had measurably shorter telomeres, a biological marker of cellular ageing, with duration of use predicting the shortening.13

• • •

The serotonin story is about memory.

Across twenty-six studies, ecstasy users showed large verbal memory impairment.2 They could not recall word lists. They forgot what they had been told minutes before. The damage was to verbal memory specifically. Visual memory was comparatively spared.

Put former ecstasy users in a brain scanner eighteen months after they quit and their serotonin transporter levels look approximately normal.4,5 The chemistry recovers. The memory tests tell a different story. One research group found that memory performance did not correlate with brain chemistry or with how long people had been clean.6 The plumbing repairs itself. The function it served does not.

The best explanation researchers have is that the damage is to the fine branching of serotonin neurons, not just the transporter protein that brain scans measure. The wiring frays. The scan looks fine. The wiring stays frayed.

The brain chemistry normalises. The memory does not come back.

• • •

Mephedrone does both of these things at once. It hits serotonin like MDMA and dopamine like methamphetamine, simultaneously.1 No single analog study captures the full picture. The predicted damage is the combination: memory loss from the serotonin side and reward deficiency from the dopamine side and the Parkinson's risk and the accelerated ageing.

Mephedrone has a property that makes the dose problem worse. Its high is shorter than MDMA's. An hour or two, against four to six.14 It wears off and you take more. A typical MDMA session involves one or two doses. A typical mephedrone session involves many, with total consumption often reaching half a gram to two grams.15 The long-term MDMA studies that found memory damage were mostly conducted on people using monthly or quarterly, at much lower total doses. Weekly mephedrone users exceed those exposures by a wide margin.

Then there is sleep.

If you use on a weekend and stay up all night, or two nights, you are adding a second injury. Sleep deprivation compounds the drug damage, and the compounding is not additive. It is multiplicative. In animal studies, MDMA given after seventy-two hours of sleep deprivation produced greater neurotoxicity than MDMA alone.16 Methamphetamine combined with sleep deprivation produced worse outcomes than either on its own.17

Both mephedrone and MDMA become more neurotoxic at higher body temperatures.18 Sleep deprivation impairs your body's ability to regulate its own temperature. Dancing in a hot room while sleep-deprived on a serotonin-releasing drug is the precise set of conditions under which these drugs do their worst damage.

Sleep deprivation also impairs the prefrontal cortex, the part of your brain that evaluates whether your own behaviour is a problem.19 Sleep debt accumulates linearly. Recovery sleep does not fully pay it off.20,21 The worse the debt, the less you are able to perceive it. You will not notice it happening.

• • •
1 year 3 years 5 years 10 years
Daily Never recovering between sessions. Cognitive decline underway. Dependence likely. Memory deficits probably permanent. Psychosis risk elevated. Relationships and career disrupted. Dopamine system aged decades. Parkinson's risk accruing. Mortality risk approaching 12x the general population. If still using: extremely high mortality risk. If stopped years ago: partial recovery, but verbal memory and some brain structures do not fully return.
Weekly, with all-nighters Chronic fatigue and mood disruption. Never fully clearing the last session before the next one. Sleep debt compounding. Memory impairment entrenching. Reward system dulling. Social and professional consequences accumulating. Converging with daily-use outcomes, delayed. Memory deficits likely persistent even if you stop now. Parkinson's risk elevated. Cardiovascular damage compounded. Memory impaired relative to peers who did not use.
Fortnightly Sub-acute effects mostly resolve between sessions. Main risk: frequency creep. Memory effects emerging. Mood and sleep measurably worse than non-users. Verbal memory deficits likely detectable on testing. Some dopamine effects uncertain at this frequency. Memory profile resembling moderate MDMA users. Mood and wellbeing measurably worse than non-using peers.
Monthly Effects resolve fully between sessions. Main risks are acute: cardiac events, unknown powder contents. Cumulative exposure low. Memory effects, if any, subtle. Chief danger is that monthly drifts to fortnightly. Mild memory effects possible after ~60 sessions. Main risk remains dose escalation over time. ~120 lifetime sessions. Verbal memory effects likely. Mood slightly worse than non-users. If you stop: good recovery prospects.
• • •

If you stop, some things recover. Serotonin transporter levels return to near-normal within twelve to eighteen months.4,5 Dopamine transporters recover partially (16 to 19 percent) over a similar period, though heavier users recover less.8 Overall cognitive function improves over two years of abstinence. After three or more years, most former users test in the normal range, though still slightly below matched controls on about a quarter of measures.22

Some things do not recover.

Verbal memory, in the studies available, does not improve with longer abstinence.3,6 Parkinson's risk, once elevated by dopamine neuron loss, does not reverse. Normal ageing continues to deplete what remains.11 Some structural brain changes are described in the literature as "hard-to-recover."23 Former users five years clean still score worse on depression, impulsivity, and sleep quality than people who never used.7

Earlier is better. Higher doses predicted less dopamine transporter recovery.8 Most cognitive gains happen in the first two years. There is no cliff the literature can point to, no single irreversible threshold. But the longer and heavier the use, the less complete the repair.

Everything above assumes the powder is mephedrone. Since 2010, you do not know that. Post-ban analysis has found other cathinones, caffeine, lidocaine, entirely different stimulants sold as MCAT. Some of those substances (MDPV, alpha-PVP) are far more dangerous. WEDINOS will test your drugs for free, by post, anonymously. No name. No consequences.

If you experience chest pain, breathing difficulty, sustained paranoia, psychosis, or seizures during or after use, that is an emergency. Call 999.

Samaritans: 116 123 (free, 24/7). Text SHOUT to 85258.

Talk to FRANK: 0300 123 6600. Or ask your GP for a substance misuse referral.


Notes

  1. Ecker et al. (2023). Mephedrone produces full release at human serotonin transporters, partial release at dopamine transporters. PubMed 37703919.
  2. Laws & Kokkalis (2007). Meta-analysis of 26 studies: verbal memory d = -1.00, visual memory d = -0.27 in ecstasy users. Hum Psychopharmacol, PMID 17621368.
  3. Ung et al. (2025). Systematic review and meta-analysis: memory deficits in abstinent MDMA users (g = -1.37); no improvement with longer abstinence. J Psychopharmacol, PMID 41255336.
  4. Buchert et al. (2003). PET study (n=117): former MDMA users' serotonin transporter levels "very close" to drug-naive controls. J Nucl Med, PMID 12621003.
  5. Buchert et al. (2004). Voxel-based PET: no serotonin transporter difference between former users and controls after extended abstinence. Am J Psychiatry, PMID 15229049.
  6. Reneman et al. (2001). SPECT imaging: cortical serotonin recovers, but memory deficits persist and do not correlate with transporter levels or abstinence duration. Arch Gen Psychiatry, PMID 11576026.
  7. Taurah et al. (2014). n=997: former MDMA users (~5yr abstinence) worse on 10/13 psychological measures vs controls. Psychopharmacology, PMID 24114426.
  8. Volkow et al. (2001). PET: 24-30% dopamine transporter loss in chronic methamphetamine users (~40 years of normal ageing); partial recovery at 12-17 months. J Neurosci, PMC6763886.
  9. Volkow et al. (2001). PET: 16% D2 receptor reduction; correlated with orbitofrontal metabolism and impulsivity. Am J Psychiatry, PMID 11729018.
  10. Wang et al. (2012). D2 receptor levels predicted relapse vs sustained abstinence at 9 months. Mol Psychiatry, PMC3261322.
  11. Curtin et al. (2015). Utah population study, 15-year follow-up: 2.8x Parkinson's risk in amphetamine users; cocaine users showed no elevated risk. Drug Alcohol Depend, PMC4295903.
  12. Callaghan et al. (2010). California hospital discharge data: HR 2.65 for Parkinson's in methamphetamine users. Mov Disord, PMID 20737543.
  13. Zhao et al. (2020). Shorter telomeres in young methamphetamine users; duration of use predicted shortening. Transl Psychiatry, PMID 34628468.
  14. Papaseit et al. (2016). Clinical pharmacology: mephedrone peaks earlier and has shorter duration than MDMA. Neuropsychopharmacology.
  15. Morgan (2018). Mephedrone-specific: 0.5-2g typical session consumption; 4+ days of mood/fatigue effects in regular users. Psychopharmacology, PMC6132682.
  16. Almeida et al. (2011). Mice: MDMA after 72h sleep deprivation produced greater neurotoxicity than MDMA alone. PMID 21071548.
  17. Alipour et al. (2024). Methamphetamine + 48h REM sleep deprivation: worse outcomes than either alone. PMID 38936532.
  18. Parrott (2012). MDMA + physical activity increased core body temperature >1°C; neurotoxicity is temperature-dependent. PMID 21924843.
  19. Van Dongen et al. (2003). Sleep restriction to ≤6h: cognitive deficits accumulated linearly; subjects unaware of their own deterioration. Sleep, PMID 12683469.
  20. Worley et al. (2021). After 5 nights of 4h sleep, 4 full recovery nights did not restore attention performance. PMID 33274389.
  21. Basner et al. (2021). Six-week sleep restriction: weekend recovery sleep did not restore all cognitive domains. PMID 33630069.
  22. Salo et al. (2009). Stroop interference normalised in long-term abstinent methamphetamine users. PMID 19339145.
  23. Okita et al. (2020). Gray matter: hippocampus and accumbens recover with abstinence; superior frontal gyri described as "hard-to-recover." BMC Psychiatry, PMC7146984.
  24. Ahman et al. (2024). Swedish national register (n=5,018; 2013-2017): standardised mortality ratio 12.4 (95% CI 11.3-13.6) in ATS users; leading cause overdose (28.9%). Addict Behav Rep, PMID 38800761.